A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma

Author： Cecchi Michele  

Publisher： Springer Publishing Company

ISSN： 2210-7703

Source： International Journal of Clinical Pharmacy, Vol.35, Iss.3, 2013-06, pp. : 483-487

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Irinotecan and bevacizumab in recurrent glioblastoma multiforme

By Jakobsen Jan Nyrop   Hasselbalch Benedikte   Stockhausen Marie-Thééréése   Lassen Ulrik   Poulsen Hans Skovgaard  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 5, 2011-04 ,pp. : 825-833

Informa Healthcare

Access to resources Recommend Favorite

Off-label use of bevacizumab linked to eye inflammation

By  

Reactions Weekly, Vol. 1, Iss. 1234, 2009-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Off-label prescribing to children in primary care: retrospective observational study

By Ekins-Daukes Suzie   Helms Peter   Simpson Colin   Taylor Michael   McLay James  

European Journal of Clinical Pharmacology, Vol. 60, Iss. 5, 2004-07 ,pp. : 349-353

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab ± irinotecan beneficial for glioblastoma

By  

Inpharma, Vol. 1, Iss. 1640, 2008-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Off-Label Use of Bevacizumab for the Treatment of Age-Related Macular Degeneration: What is the Evidence?

By Ziemssen Focke  

Drugs & Aging, Vol. 26, Iss. 4, 2009-05 ,pp. : 295-320

Adis International

Access to resources Recommend Favorite